Hilmi Erdem Gözden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hilmi Erdem Gözden has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Emrah Kılıçaslan
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey
2 shared publications - Meltem Aylı
Department of Hematology, Gülhane Training and Research Hospital, Ankara 06010, Türkiye
2 shared publications - Muhammet Kürşat Kaptan
Division of Hematology, Department of Internal Medicine, Health Science University, Sultan Abdulhamid Han Training and Research Hospital
2 shared publications - Murat Yıldırım
Department of Hematology, Gülhane Training and Research Hospital, Ankara 06010, Türkiye
2 shared publications - Selim Sayın
Department of Hematology, Gülhane Training and Research Hospital, Ankara 06010, Türkiye
2 shared publications - Tayfun Elibol
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey
2 shared publications
Latest Publications
- Open Access
- 11 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7841
Infectious Burden and Immortal-Time Bias During AML Induction: A Supportive-Care Cohort Under Posaconazole Prophylaxis
Background/Objectives: Infection is a major complication of acute myeloid leukaemia (AML) induction, and analyses relating treatment-emergent infection to survival are prone to immortal-time bias. We characterised baseline and treatment-emergent infection during induction and used bias-aware methods to distinguish a pre-treatment risk signal from a survival-time artefact. Methods: Our study analysed a retrospective single-centre cohort of 91 adults with newly diagnosed AML receiving induction under universal posaconazole prophylaxis (2019–2025) with Cox models, 14- and 30-day landmark analyses and Firth penalised logistic regression. Results: Active infection at diagnosis occurred in 23/91 (25.3%) and treatment-emergent infection in 54/91 (59.3%). A naive Cox model showed an implausibly protective association for treatment-emergent infection (hazard ratio [HR] 0.46, 95% CI 0.21–0.99). In 14- and 30-day landmark analyses (HR 0.59 and 0.60; 95% CIs included 1) the estimate moved toward the null and lost statistical significance; because infection-onset dates were unavailable, landmark analysis only partially corrects this bias, and the independent association between treatment-emergent infection and survival could not be reliably estimated. Active infection at diagnosis showed a fragile, exploratory association with later mortality that was nominally significant in only one of several pre-specified specifications (30-day landmark HR 2.56, 95% CI 1.03–6.37). Conclusions: The apparently protective association of treatment-emergent infection with survival is consistent with immortal-time bias; it is a complication and marker of course, not a survival determinant. Baseline infection is a hypothesis-generating candidate pre-treatment risk marker that requires prospective validation.
- 11 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7841
Open AccessInfectious Burden and Immortal-Time Bias During AML Induction: A Supportive-Care Cohort Under Posaconazole Prophylaxis
Background/Objectives: Infection is a major complication of acute myeloid leukaemia (AML) induction, and analyses relating treatment-emergent infection to survival are prone to immortal-time bias. We characterised baseline and treatment-emergent infection during induction and used bias-aware methods to distinguish a pre-treatment risk signal from a survival-time artefact. Methods: Our study analysed a retrospective single-centre cohort of 91 adults with newly diagnosed AML receiving induction under universal posaconazole prophylaxis (2019–2025) with Cox models, 14- and 30-day landmark analyses and Firth penalised logistic regression. Results: Active infection at diagnosis occurred in 23/91 (25.3%) and treatment-emergent infection in 54/91 (59.3%). A naive Cox model showed an implausibly protective association for treatment-emergent infection (hazard ratio [HR] 0.46, 95% CI 0.21–0.99). In 14- and 30-day landmark analyses (HR 0.59 and 0.60; 95% CIs included 1) the estimate moved toward the null and lost statistical significance; because infection-onset dates were unavailable, landmark analysis only partially corrects this bias, and the independent association between treatment-emergent infection and survival could not be reliably estimated. Active infection at diagnosis showed a fragile, exploratory association with later mortality that was nominally significant in only one of several pre-specified specifications (30-day landmark HR 2.56, 95% CI 1.03–6.37). Conclusions: The apparently protective association of treatment-emergent infection with survival is consistent with immortal-time bias; it is a complication and marker of course, not a survival determinant. Baseline infection is a hypothesis-generating candidate pre-treatment risk marker that requires prospective validation.
- 7 September 2026
- Published by Elsevier in Cytotherapy
- Vol. 29 (1) , 103003
Calibrated prediction of CD34+ yield and apheresis product CD34+ concentration for allogeneic donor collection planning
- 7 September 2026
- Published by Elsevier in Cytotherapy
- Vol. 29 (1) , 103003
Calibrated prediction of CD34+ yield and apheresis product CD34+ concentration for allogeneic donor collection planning
- Open Access
- 4 August 2026
- Published by Springer Nature in BMC Medical Education
- Vol. 26 (1)
Knowledge, attitudes, and use of artificial intelligence among adult and pediatric hematologists in Türkiye: a national cross-sectional survey
- 4 August 2026
- Published by Springer Nature in BMC Medical Education
- Vol. 26 (1)
Open AccessKnowledge, attitudes, and use of artificial intelligence among adult and pediatric hematologists in Türkiye: a national cross-sectional survey
- Open Access
- 29 October 2024
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 6 (4) , 163-166
Isolated Langerhans Cell Histiocytosis of the Thyroid: A very rare case report
Langerhans cell histiocytosis (LCH) is a group of diseases that cause damage by local or widespread accumulation of atypical histiocytes in various tissues such as skin, bone, lung, liver, lymph nodes, mucocutaneous tissues, and endocrine organs. LCH was detected as a result of a total thyroidectomy biopsy performed on a 43-year-old female patient with a solitary euthyroid nodule following weight loss and an increase in the size of the thyroid nodule during outpatient clinic checks. Patient's whole body positron emission tomography. The case of LCH with isolated thyroid involvement is very rare, and a limited number of cases have been presented on this subject. In addition, it will contribute to the literature since there are fewer than ten LCH cases with thyroid involvement.
- 29 October 2024
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 6 (4) , 163-166
Open AccessIsolated Langerhans Cell Histiocytosis of the Thyroid: A very rare case report
Langerhans cell histiocytosis (LCH) is a group of diseases that cause damage by local or widespread accumulation of atypical histiocytes in various tissues such as skin, bone, lung, liver, lymph nodes, mucocutaneous tissues, and endocrine organs. LCH was detected as a result of a total thyroidectomy biopsy performed on a 43-year-old female patient with a solitary euthyroid nodule following weight loss and an increase in the size of the thyroid nodule during outpatient clinic checks. Patient's whole body positron emission tomography. The case of LCH with isolated thyroid involvement is very rare, and a limited number of cases have been presented on this subject. In addition, it will contribute to the literature since there are fewer than ten LCH cases with thyroid involvement.
- 16 February 2023
- Published by Galenos Yayinevi in Hamidiye Medical Journal
- Vol. 4 (1) , 63-69
Serum Lactate Dehydrogenase Elevates and Inversely Correlates with Platelet Count in Immune Thrombocytopenia: A Case-control Study in Adults
- 16 February 2023
- Published by Galenos Yayinevi in Hamidiye Medical Journal
- Vol. 4 (1) , 63-69
Serum Lactate Dehydrogenase Elevates and Inversely Correlates with Platelet Count in Immune Thrombocytopenia: A Case-control Study in Adults
- Open Access
- 30 December 2022
- Published by Mugla Sitki Kocman University in Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi
- Vol. 9 (3) , 215-220
Higher Survival Advantage with Hyper-CVAD Chemotherapy Regimen Before Allogeneic Stem Cell Transplantation in Patients with High Risk Adult Acute Lymphoblastic Leukemia: Two-Center Experience
While promising results have been achieved in the treatment of childhood, the optimal initial treatment for adult acute lymphoblastic leukemia (ALL) has not yet been defined. Hyper-CVAD has become a widely used treatment for approximately 2 decades in the treatment of adult ALL. We conducted a retrospective analysis of 30 patients treated with Hyper-CVAD at two centers between 2014 and 2020. In all (n=30) patients treated with Hyper-CVAD, complete response (CR) rate was 86.7%, induction mortality was 10%, refractory disease was 3.3%, the median overall survival (OS) was 38 months (95% CI 7.78–68.2 months), the median disease-free survival (DFS) was 29 months (95% CI 9–49 months), the 2-year OS rate was 56.5%, and the 2-year DFS was rate 56.7%. For standard risk (n=12) ALL patients, the median OS was 20 months (95% CI 0–43 months), and median DFS was 7 months (95% CI 0–25 months). For high risk (n=18) ALL patients, the median OS was 38 months (95% CI 0–76 months), and median DFS was not reached. These results indicate that Hyper-CVAD regimen should be considered as an option for induction treatment of adult ALL patients who are newly diagnosed and eligible for allo-HSCT.
- 30 December 2022
- Published by Mugla Sitki Kocman University in Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi
- Vol. 9 (3) , 215-220
Open AccessHigher Survival Advantage with Hyper-CVAD Chemotherapy Regimen Before Allogeneic Stem Cell Transplantation in Patients with High Risk Adult Acute Lymphoblastic Leukemia: Two-Center Experience
While promising results have been achieved in the treatment of childhood, the optimal initial treatment for adult acute lymphoblastic leukemia (ALL) has not yet been defined. Hyper-CVAD has become a widely used treatment for approximately 2 decades in the treatment of adult ALL. We conducted a retrospective analysis of 30 patients treated with Hyper-CVAD at two centers between 2014 and 2020. In all (n=30) patients treated with Hyper-CVAD, complete response (CR) rate was 86.7%, induction mortality was 10%, refractory disease was 3.3%, the median overall survival (OS) was 38 months (95% CI 7.78–68.2 months), the median disease-free survival (DFS) was 29 months (95% CI 9–49 months), the 2-year OS rate was 56.5%, and the 2-year DFS was rate 56.7%. For standard risk (n=12) ALL patients, the median OS was 20 months (95% CI 0–43 months), and median DFS was 7 months (95% CI 0–25 months). For high risk (n=18) ALL patients, the median OS was 38 months (95% CI 0–76 months), and median DFS was not reached. These results indicate that Hyper-CVAD regimen should be considered as an option for induction treatment of adult ALL patients who are newly diagnosed and eligible for allo-HSCT.
- Open Access
- 22 December 2022
- Published by Gumushane University in Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 11 (4) , 1699-1714
Non-Hodgkin Lenfoma ve COVID-19 Pnömonisi olan Hastanın Bireyselleştirilmiş Bakımı: Olgu Sunumu
Lenfoma hastalarının Koronavirüs Hastalığı 2019 (COVID-19)’a yakalanma riskinin yüksek olduğu ve yakalanmaları halinde hastalığın seyrini kötüleştirebileceği bilinmektedir. COVID-19 hastalığı ve hematolojik kanserli hastaların bakım ve tedavisinde, multidisipliner yaklaşım önem kazanmaktadır. Multidisipliner ekipte hastanın bakımından sorumlu olan hemşireler, hemşirelik bakımını bireyselleştirilmiş ve bütüncül olarak sunmaktadır. Bu olgu sunumunda Non-hodgkin Lenfoma takipli ve COVID-19 enfeksiyonu sonucu pnömoni gelişen bir olgunun yoğun bakım ünitesindeki hemşirelik bakımı, bilimsel sorun çözümleme yöntemi olan hemşirelik süreci doğrultusunda planlanmıştır. Öksürük, ateş, halsizlik şikayetleri ile hastanenin acil kliniğine başvuran hastanın Polimeraz Zincir Reaksiyonu (PCR-Polymerase Chain Reaction) testi negatif idi. Ancak, hastanın kliniğine yatışının 37 inci gününde vücut sıcaklığının 40.1ºC ve toraks görüntülemesinde COVID-19 şüphesi olması nedeniyle yapılan PCR testi sonucu pozitif bulundu. Desatüre olarak dahiliye yoğun bakım ünitesine kabul edilen hasta, kabulünün beşinci gününde entübe edildi. Yoğun bakımda bulunduğu sürede (14 gün) hedef/beklenen hasta sonuçlarına ulaşmak için bireye özgü hemşirelik girişimleri uygulandı. Bu olgu sunumunun hemşirelere ve sağlık ekibi üyelerine rehber olacağı, aynı zamanda bakımın kalitesini arttırmak için veri olacağı düşünülmektedir.
- 22 December 2022
- Published by Gumushane University in Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 11 (4) , 1699-1714
Open AccessNon-Hodgkin Lenfoma ve COVID-19 Pnömonisi olan Hastanın Bireyselleştirilmiş Bakımı: Olgu Sunumu
Lenfoma hastalarının Koronavirüs Hastalığı 2019 (COVID-19)’a yakalanma riskinin yüksek olduğu ve yakalanmaları halinde hastalığın seyrini kötüleştirebileceği bilinmektedir. COVID-19 hastalığı ve hematolojik kanserli hastaların bakım ve tedavisinde, multidisipliner yaklaşım önem kazanmaktadır. Multidisipliner ekipte hastanın bakımından sorumlu olan hemşireler, hemşirelik bakımını bireyselleştirilmiş ve bütüncül olarak sunmaktadır. Bu olgu sunumunda Non-hodgkin Lenfoma takipli ve COVID-19 enfeksiyonu sonucu pnömoni gelişen bir olgunun yoğun bakım ünitesindeki hemşirelik bakımı, bilimsel sorun çözümleme yöntemi olan hemşirelik süreci doğrultusunda planlanmıştır. Öksürük, ateş, halsizlik şikayetleri ile hastanenin acil kliniğine başvuran hastanın Polimeraz Zincir Reaksiyonu (PCR-Polymerase Chain Reaction) testi negatif idi. Ancak, hastanın kliniğine yatışının 37 inci gününde vücut sıcaklığının 40.1ºC ve toraks görüntülemesinde COVID-19 şüphesi olması nedeniyle yapılan PCR testi sonucu pozitif bulundu. Desatüre olarak dahiliye yoğun bakım ünitesine kabul edilen hasta, kabulünün beşinci gününde entübe edildi. Yoğun bakımda bulunduğu sürede (14 gün) hedef/beklenen hasta sonuçlarına ulaşmak için bireye özgü hemşirelik girişimleri uygulandı. Bu olgu sunumunun hemşirelere ve sağlık ekibi üyelerine rehber olacağı, aynı zamanda bakımın kalitesini arttırmak için veri olacağı düşünülmektedir.